Brief: Dermata - On Dec 15, 2022 Received Letter From Nasdaq Of Extension To June 12, 2023 To Regain Compliance With Minimum Bid Price Requirement - Filing
15/12/2022 21:28
Dec 15 (Reuters) - Dermata Therapeutics Inc DRMA.O :
* DERMATA - ON DEC 15, 2022 RECEIVED LETTER FROM NASDAQ OF
EXTENSION TO JUNE 12, 2023 TO REGAIN COMPLIANCE WITH MINIMUM BID
PRICE REQUIREMENT
Further company coverage: DRMA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview